临床分离肺炎克雷伯菌对氯硝柳胺联合外排泵抑制剂PaβN的适应性:抗菌药物交叉耐药
研究将抗蠕虫药氯硝柳胺与外排泵抑制剂苯丙氨酸-精氨酸-β-萘酰胺(PaβN)联用,针对6株携带不同碳青霉烯酶的临床肺炎克雷伯菌分离株。体外棋盘试验显示两药对6株菌均有协同效应,但每8小时重复暴露后出现适应性,PaβN的MIC升高6至12倍,并伴随AcrAB-TolC外排泵调控基因突变及对多种抗菌药物的交叉耐药。
要点
- 氯硝柳胺与PaβN对6株产碳青霉烯酶肺炎克雷伯菌临床分离株体外均呈协同效应。
- 每8小时重复暴露后出现适应性,PaβN的MIC升高6至12倍。
- 适应性分离株存在ramR和acrR突变,并出现对多种抗菌药物的交叉耐药。
核心结论
- 尽管初步体外阶段可能提示氯硝柳胺与PaβN联用具有协同效应,但药物与外排泵抑制剂的组合可能产生与抗菌药物耐药相关的适应性表型,必须加以考虑。
研究设计与样本
- 研究纳入6株携带不同碳青霉烯酶的临床肺炎克雷伯菌分离株,采用肉汤微量稀释法和棋盘试验测定氯硝柳胺与PaβN的MIC,并进行时间-杀菌曲线。
- 将细菌每8小时重复暴露于相同浓度的氯硝柳胺和/或PaβN以获得适应性分离株,测定其存活率。
- 对acrAB-tolC基因及其调控基因进行测序,并用定量RT-PCR比较适应性分离株与非适应性分离株中acrA基因的表达。
- 最后测定适应性分离株对多种抗菌药物的MIC。
主要发现
- 氯硝柳胺与PaβN对6株分离株在体外均具有协同效应。
- 每8小时向培养基中重复给药后出现适应性,PaβN的MIC升高6至12倍。
- 测序发现三元外排泵AcrAB-TolC的调控基因ramR和acrR存在不同突变,可能负责外排泵过表达及对该组合的适应性。
- 适应性分离株对多种抗菌药物出现交叉耐药,证实了AcrAB-TolC外排泵的过表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To search for new means of combatting carbapenemase-producing strains of Klebsiella pneumoniae by repurposing the anti-helminth drug niclosamide as an antimicrobial agent and combining it with the efflux pump inhibitor (EPI) phenyl-arginine-β-naphthylamide (PaβN). METHODS: Niclosamide and PaβN MICs were determined for six clinical K. pneumoniae isolates harbouring different carbapenemases by broth microdilution and chequerboard assays. Time-kill curves in the presence of each drug alone and in combination were conducted. The viability of bacterial cells in the presence of repetitive exposures at 8 h to the treatment at the same concentration of niclosamide and/or PaβN (adapted isolates) was determined. The acrAB-tolC genes and their regulators were sequenced and quantitative RT-PCR was performed to assess whether the acrA gene was overexpressed in adapted isolates compared with non-adapted isolates. Finally, the MICs of several antimicrobials were determined for the adapted isolates. RESULTS: Niclosamide and PaβN had synergistic effects on the six isolates in vitro, but adaptation appeared when the treatment was applied to the medium every 8 h, with an increase of 6- to 12-fold in the MIC of PaβN. Sequencing revealed different mutations in the regulators of the tripartite AcrAB-TolC efflux pump (ramR and acrR) that may be responsible for the overexpression of the efflux pump and the adaptation to this combination. Co-resistance to different antimicrobials confirmed the overexpression of the AcrAB-TolC efflux pump. CONCLUSIONS: Despite the synergistic effect that preliminary in vitro stages may suggest, the combinations of drugs and EPI may generate adapted phenotypes associated with antimicrobial resistance that must be taken into consideration.
引用
- Pacios O, Fernández-García L, Bleriot I, et al. Adaptation of clinical isolates of Klebsiella pneumoniae to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine-β-naphthylamide (PaβN): co-resistance to antimicrobials. J Antimicrob Chemother. 2022. PMID: 35238930. doi:10.1093/jac/dkac044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。